Pertussis: A Persistent Cause of Morbidity and Mortality in Young Infants

Cantey, Joseph B.; Sánchez, Pablo J.; Tran, Judy; Chung, Wendy; Siegel, Jane D.

doi:10.1016/j.jpeds.2014.01.023

Cited by 16 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the timing of vaccine administration is important to avoid a time window at higher risk of maternal infection and infant exposure [66,67]. According to this, cocooning may be limited in its ability to prevent neonatal pertussis in the early weeks of life because the disease may already be circulating within the household at the time of delivery and may therefore be transmitted before vaccine-induced immunity develops in the contacts [67][68][69]. A recent trial evaluated the kinetics of immediate antibody response to Tdap in post-partum women demonstrating that serum IgG and IgA antibodies were not detectable until 5-7 days after vaccine receipt.…”

Section: Management and Prevention Of Pertussis Infection In Neonatesmentioning

confidence: 99%

Management and prevention of pertussis infection in neonates

Berti

Venturini

Galli

et al. 2014

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Despite the fact that universal immunization against pertussis led to a dramatic decrease in the incidence and mortality in high-income countries, it has left a window of vulnerability for newborns. Although specific guidelines concerning management of neonatal whooping cough have not yet been developed, the present review summarizes the main available recommendations on diagnostic work-up and treatment of neonatal pertussis. Additionally, new prevention strategies are explored, including the use of an additional booster dose of vaccine to adolescents and adults, vaccination of healthcare workers, immunization of household contacts and caregivers (cocooning strategy), vaccination of pregnant women and, finally, neonatal immunization with novel vaccines. These strategies are analyzed and discussed in terms of efficacy, safety and cost-effectiveness.

show abstract

Section: Management and Prevention Of Pertussis Infection In Neonatesmentioning

confidence: 99%

Management and prevention of pertussis infection in neonates

Berti

Venturini

Galli

et al. 2014

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

show abstract

“…1 Vaccine-preventable diseases such as pertussis and invasive meningococcal or pneumococcal infections still cause severe illness, disabilities and death despite high levels of vaccine coverage. [2][3][4][5][6][7] Analysis of a pertussis outbreak in 2010 showed that 140/275 (51%) infants with pertussis could have had 1 dose of the vaccine and 22% at least 2 doses. 2 The main reason is a delay or failure to vaccinate some patients, resulting in the absence of protection.…”

Section: Introductionmentioning

confidence: 99%

What timing of vaccination is potentially dangerous for children younger than 2 years?

Gras

Bailly

Lagrée

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Vaccine-preventable diseases still occur although measured coverage rates at 2 y of age are high. The occurrence of these diseases may be explained in part by untimely, that is, late vaccination. Our objective was to identify potentially dangerous vaccination delays for each dose of each vaccine in children younger than 2 y. A 3-round Delphi process was conducted by e-mail. We recruited 37 French experts in vaccines for children: 16 from the Infovac-France group and 21 from the French study group for pediatric infectious diseases. Items were generated by a literature review for the 10 vaccine doses recommended before 2 y of age. Item reduction in round 1 and 2 and any consensus in round 3 used a 70% consensus cutoff. The mean participation rate was 79%. Delays that should not be exceeded were identified for all vaccine doses. The 70% consensus was reached for 6 of the 10 vaccine doses: 15 d after the recommended date for the first 2 doses of the diphtheria-tetanus-acellular pertussis-inactivated polio vaccine/Haemophilus influenzae b vaccine and for the second dose of the pneumococcal conjugate vaccine, 1 month for the meningococcal C vaccine and for the first dose of the measles-mumps-rubella vaccine, and 11 y of age for completion of the hepatitis B vaccination. This Delphi process identified potentially dangerous vaccination delays for children to the age of 2 y. These can be used as new indicators in further studies of vaccine effectiveness and can help to improve the quality of vaccine protection in children.

show abstract

“…Parents and household contacts are often considered as a primary source of pertussis infection for infants 1 and for those non-immunized against pertussis a risk of severe clinical illness and death has been recognized. 2,3 It is widely shared the need to confirm a suspected pertussis case with a laboratory assay. One of the method of choice is the realtime PCR on nasopharyngeal aspirate or swab able to differentiate among Bordetellae species.…”

mentioning

confidence: 99%